Business Context and Reporting Period
Company: Werewolf Therapeutics, Inc. (HOWL)
Filing Type: Form 8-K (Current Report)
Date of Report: August 14, 2026
Event: Entry into a Material Definitive Agreement involving the sale of specific assets and a related license agreement with EMD Serono Research & Development Institute Inc. (EMD).
Key Financial Metrics and Transaction Terms
This filing details a specific transaction rather than periodic financial performance. Key financial terms include:
- Upfront Consideration: $28.0 million payable by EMD to Werewolf Therapeutics.
- Milestone Payment: $5.0 million payable upon completion of the technology transfer.
- Total Immediate Consideration: $33.0 million (subject to transfer completion).
- Assets Sold: Pre-clinical INDUCER platform (patents, know-how, compounds) and INDUKINE platform (certain patents, know-how, compounds).
- Assets Retained: Clinical development programs for WTX-124 and WTX-330.
Note: The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity for the reporting period.
Material Changes and Strategic Impact
The Company has divested its pre-clinical INDUCER and INDUKINE platforms while retaining rights to its clinical programs (WTX-124 and WTX-330). To facilitate the continued development of these retained programs, EMD granted Werewolf an exclusive license to certain patents included in the transferred assets. Additionally, the agreement enables Werewolf to maintain existing sublicense arrangements with Harpoon Therapeutics, Inc. and Jazz Pharmaceuticals Ireland Limited.
Guidance, Risks, and Covenants
- Non-Competition Covenant: Werewolf agreed not to exploit compounds or programs directed to the same tumor target as the Transferred Compounds for 24 months post-closing, subject to change of control exceptions.
- Indemnification: Both parties agreed to indemnify each other for losses arising from breaches of representations, warranties, and covenants.
- Future Filings: The full text of the Purchase Agreement and License Agreement will be filed in a subsequent SEC report.
Investor Verification Checklist
- Verify the exact closing date and conditions precedent for the $5.0 million milestone payment.
- Confirm the specific scope of the exclusive license granted back to Werewolf for WTX-124 and WTX-330 development.
- Review the subsequent filing for the full Purchase Agreement to understand indemnification caps and specific non-competition exceptions.
- Assess the impact of the 24-month non-compete restriction on Werewolf's future pipeline development in the same tumor targets.